Michael S Rogers

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc The albino mutation of tyrosinase alters ocular angiogenic responsiveness
    Michael S Rogers
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA
    Angiogenesis 16:639-46. 2013
  2. ncbi request reprint Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth
    Michael S Rogers
    Vascular Biology Program and Department of Ophthalmology, Children s Hospital, and Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 67:9980-5. 2007
  3. ncbi request reprint Genetic loci that control the angiogenic response to basic fibroblast growth factor
    Michael S Rogers
    Vascular Biology Program, Children s Hospital, and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02115, USA
    FASEB J 18:1050-9. 2004
  4. pmc 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose Inhibits Angiogenesis via Inhibition of Capillary Morphogenesis Gene 2
    Lorna M Cryan
    Vascular Biology Program, Department of Surgery, Boston Children s Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, Massachusetts 02115, United States
    J Med Chem 56:1940-5. 2013
  5. pmc Genetic loci that control the size of laser-induced choroidal neovascularization
    Kei Nakai
    Department of Surgery, Vascular Biology Program, Children s Hospital Boston, 300 Longwood Ave, Boston, MA 02115, USA
    FASEB J 23:2235-43. 2009
  6. pmc Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy
    Lorna M Cryan
    Department of Surgery, Children s Hospital Boston, Boston, MA 02115, USA
    Front Biosci (Landmark Ed) 16:1574-88. 2011
  7. doi request reprint Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay
    Lorna M Cryan
    Boston Children s Hospital, Harvard Medical School, Vascular Biology Program, Department of Surgery, Karp 11, 300 Longwood Ave, Boston, MA 02115, USA
    J Biomol Screen 18:714-25. 2013
  8. pmc A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein
    Michael S Rogers
    Department of Surgery, Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e39911. 2012
  9. ncbi request reprint The mouse cornea micropocket angiogenesis assay
    Michael S Rogers
    The Vascular Biology Program, Children s Hospital Boston, and Department of Ophthalmology, Harvard Medical School, 300 Longwood Ave, Boston, Massachusetts 02115, USA
    Nat Protoc 2:2545-50. 2007
  10. ncbi request reprint Genetic loci that control vascular endothelial growth factor-induced angiogenesis
    Michael S Rogers
    Division of Surgical Research, Children s Hospital, and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02115, USA
    FASEB J 17:2112-4. 2003

Collaborators

Detail Information

Publications16

  1. pmc The albino mutation of tyrosinase alters ocular angiogenic responsiveness
    Michael S Rogers
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA
    Angiogenesis 16:639-46. 2013
    ..These results may partially explain increased aggressiveness in amelanotic melanoma, as well as ethnic differences in diabetic retinopathy and macular degeneration...
  2. ncbi request reprint Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth
    Michael S Rogers
    Vascular Biology Program and Department of Ophthalmology, Children s Hospital, and Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 67:9980-5. 2007
    ..These results also suggest that endothelial cell-binding proteins from additional pathogens may inhibit angiogenesis and raise the question of the role of such inhibition in pathogenesis...
  3. ncbi request reprint Genetic loci that control the angiogenic response to basic fibroblast growth factor
    Michael S Rogers
    Vascular Biology Program, Children s Hospital, and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02115, USA
    FASEB J 18:1050-9. 2004
    ..Differences in these regions may influence individual susceptibility to angiogenesis related diseases such as cancer, macular degeneration, atherosclerosis, and arthritis...
  4. pmc 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose Inhibits Angiogenesis via Inhibition of Capillary Morphogenesis Gene 2
    Lorna M Cryan
    Vascular Biology Program, Department of Surgery, Boston Children s Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, Massachusetts 02115, United States
    J Med Chem 56:1940-5. 2013
    ..Together, these results suggest that a portion of the in vivo antitumor activity of PGG may be the result of antiangiogenic activity mediated by inhibition of CMG2...
  5. pmc Genetic loci that control the size of laser-induced choroidal neovascularization
    Kei Nakai
    Department of Surgery, Vascular Biology Program, Children s Hospital Boston, 300 Longwood Ave, Boston, MA 02115, USA
    FASEB J 23:2235-43. 2009
    ..Differences in these regions may control individual susceptibility to CNV...
  6. pmc Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy
    Lorna M Cryan
    Department of Surgery, Children s Hospital Boston, Boston, MA 02115, USA
    Front Biosci (Landmark Ed) 16:1574-88. 2011
    ..Additionally, studies of modified forms of lethal toxin (LeTx) have demonstrated that targeted inhibition of MAPKs within tumor vessels may represent an efficacious anti-angiogenic strategy...
  7. doi request reprint Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay
    Lorna M Cryan
    Boston Children s Hospital, Harvard Medical School, Vascular Biology Program, Department of Surgery, Karp 11, 300 Longwood Ave, Boston, MA 02115, USA
    J Biomol Screen 18:714-25. 2013
    ..This is the first demonstration of a high-throughput screening assay that identifies inhibitors of TEM8, with potential application for antianthrax and antiangiogenic diseases. ..
  8. pmc A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein
    Michael S Rogers
    Department of Surgery, Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e39911. 2012
    ..This work represents the first reported high throughput screening assay targeting CMG2 to identify possible inhibitors of both angiogenesis and anthrax intoxication...
  9. ncbi request reprint The mouse cornea micropocket angiogenesis assay
    Michael S Rogers
    The Vascular Biology Program, Children s Hospital Boston, and Department of Ophthalmology, Harvard Medical School, 300 Longwood Ave, Boston, Massachusetts 02115, USA
    Nat Protoc 2:2545-50. 2007
    ..A skilled investigator can implant and grade 40 eyes in about 2.5 h. The results of the assay are used to assess the ability of potential therapeutic molecules or genetic differences to modulate angiogenesis in vivo...
  10. ncbi request reprint Genetic loci that control vascular endothelial growth factor-induced angiogenesis
    Michael S Rogers
    Division of Surgical Research, Children s Hospital, and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02115, USA
    FASEB J 17:2112-4. 2003
    ..Candidate angiogenesis-related genes in these regions include those for collagen XVIII/endostatin, matrix metalloproteinase 11, integrin beta2, prostaglandin D2 synthase, and interleukin-1 receptor antagonist...
  11. ncbi request reprint S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice
    Suzanne Lentzsch
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 62:2300-5. 2002
    ..We conclude that S-3APG is a powerful anti-myeloma and anti-B-cell-lymphoma agent that has both antiproliferative and antiangiogenic effects...
  12. pmc The classical pink-eyed dilution mutation affects angiogenic responsiveness
    Michael S Rogers
    Vascular Biology Program, Children s Hospital Boston, Boston, Massachusetts, United States of America
    PLoS ONE 7:e35237. 2012
    ..Using this allele, we demonstrate that pink-eyed dilution mutations in Oca2 can affect both bFGF and VEGF-induced corneal angiogenesis...
  13. pmc Phenolic compounds as antiangiogenic CMG2 inhibitors from Costa Rican endophytic fungi
    Shugeng Cao
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
    Bioorg Med Chem Lett 22:5885-8. 2012
    ..The structure of the two new compounds, A (1) and B (2), were elucidated on the basis of extensive spectroscopic analysis, including 1D and 2D NMR experiments...
  14. ncbi request reprint The effect of genetic diversity on angiogenesis
    Michael S Rogers
    Vascular Biology Program, Children s Hospital, and Department of Ophthalmology Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA
    Exp Cell Res 312:561-74. 2006
    ..Genetic alterations responsible for discrete angiogenic alterations will then be studied in appropriate mouse disease models...
  15. ncbi request reprint Antiangiogenic therapy and p53
    Timothy Browder
    Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Science 297:471; discussion 471. 2002
  16. ncbi request reprint Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis
    Yuval Shaked
    Department of Molecular and Cellular Biology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario M3N 4M5, Canada
    Cancer Cell 7:101-11. 2005
    ..Finally, treatment with a targeted VEGFR-2 antibody caused a dose-dependent reduction in viable CEPs that precisely paralleled its previously and empirically determined antitumor activity...